

Faron Pharmaceuticals Ltd

11:58 13 Jan 2020

Faron Pharmaceuticals says cancer drug trial group has been expanded

Faron Pharmaceuticals Oy (LON:FARN) (NASDAQ-FIRSTNORTH:FARON) shares rose on Monday as it said the data monitoring committee overseeing the phase I/II trial of its cancer drug has approved an expansion of the study into late-stage colorectal cancer.

The MATINS assessment is currently gauging safety and tolerability as well as the efficacy of its Clevegen treatment in people with melanoma, pancreatic, ovarian and colorectal cancer.

The drug, which can switch immune suppression to immune activation, will be administered in a low dose (0.3 milligrams per kilogram) in colorectal patients.

This dose, according to Faron, has been associated with "clinical response and has produced the strongest immune response".

In a short update on progress, the company also revealed that all doses - 0.1mg/kg to 10mg/kg - had shown "good tolerability with no dose-limiting toxicity signals".

"The decline in expression of negative immune checkpoint receptors post Clevegen dosing warrants expansion of Clevegen testing in numerous cancer types and therefore we will now ensure a rapid expansion of part II of the MATINS trial to continue investigating the safety and efficacy of Clevegen in various cancer cohort," said Faron chief executive Markku Jalkanen.

Clevegen is being assessed both as a single therapy and in combination with other existing cancer treatments. With the ability to turn off immune suppression and activate an immune response, there could be applications beyond oncology, the firm reckons.

In late morning trading, Faron Pharma shares were 3.7% higher at 282.50p.

-- Adds share price --

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

Price: 282.5

Market Cap: £122.3 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: FARN

Listing: AIM

52 week High Low
320.5 54.4891

Sector: Pharma & Biotech

Website: www.faron.com

Company Synopsis:

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

action@proactiveinvestors.com

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to
Twenty Five Thousand dollars (\$25,000).